BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$301.92 USD
+5.10 (1.72%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $302.11 +0.19 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$301.92 USD
+5.10 (1.72%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $302.11 +0.19 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
The Bears Short Real Estate Stocks: Zacks April Strategy
by John Blank
Bulls say "buy when there is blood on the streets" -- meaning buy now. The bear response is "there will another shoe to drop" -- meaning stay away.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Molina's (MOH) inorganic growth activities, financial flexibility and cost-cutting initiatives poise it well for growth.
Community Health (CYH) Divests Hospital for $92 Million
by Zacks Equity Research
Community Health (CYH) divests a healthcare facility in West Virginia, thereby reinforcing the sincere focus that it puts to shed non-core assets and use funds to grow well-performing business areas.
Verano Holdings Corp. (VRNOF) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 300% and 0.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical's (SEM) Orlando Facility to Boost Post-Acute Care
by Zacks Equity Research
Select Medical (SEM) aims to address the post-acute care demand in the Central Florida region through the construction of a specialty hospital in Orlando.
SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?
by Zacks Equity Research
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's Why You Should Retain Acadia (ACHC) in Your Portfolio
by Zacks Equity Research
Diversified revenue base, improving top line, strategic expansion initiatives and joint ventures poise Acadia Healthcare (ACHC) well for growth.
Wall Street Analysts Predict a 28.56% Upside in Bio-Rad (BIO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Bio-Rad (BIO) points to a 28.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO), owing to robust demand in Life Science and Clinical Diagnostics arms.
Bio-Rad (BIO) Global Expansion Strong, FX Woe Dents Growth
by Zacks Equity Research
Bio-Rad (BIO) experiences double-digit currency-neutral core revenue growth in the Americas and Asia in Q4.
BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
by Zacks Equity Research
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up
by Zacks Equity Research
Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Misses Q1 Earnings Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -27.27% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.
Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
by Zacks Equity Research
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.